A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52-Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Non-Cystic Fibrosis Bronchiectasis (MAHALE)
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Benralizumab (Primary)
- Indications Bronchiectasis
- Focus Registrational; Therapeutic Use
- Acronyms MAHALE
- Sponsors AstraZeneca; AstraZeneca AB
Most Recent Events
- 28 Mar 2025 Status changed from completed to discontinued.
- 27 May 2024 Status changed from active, no longer recruiting to completed.
- 05 Apr 2024 This study has been Completed in Denmark, According to European Clinical Trials Database record.